Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).

被引：0
作者：
Cavalli, Franco
Rooney, Brendan
Pei, Lixia
Van De Velde, Helgi
Robak, Tadeusz
机构：
[1] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[2] Janssen Res & Dev, High Wycombe, Bucks, England
[3] Janssen Res & Dev, Raritan, NJ USA
[4] Janssen Res & Dev, Beerse, Belgium
[5] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS
    Robak, T.
    Huang, H.
    Jin, J.
    Zhu, J.
    Liu, T.
    Samoilova, O.
    Pylypenko, H.
    Verhoef, G.
    Siritanaratkul, N.
    Osmanov, E.
    Alexeeva, J.
    Pereira, J.
    Mayer, J.
    Hong, X.
    Maeda, Y.
    Pei, L.
    Rooney, B.
    van de Velde, H.
    Cavalli, F.
    HAEMATOLOGICA, 2014, 99 : 523 - 524
  • [2] Phase 3 Study of Frontline Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Plus Vincristine (R-CHOP) or Bortezomib (VR-CAP) in Transplantation-Unsuitable Mantle Cell Lymphoma (MCL) Patients
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 9 - 11
  • [3] Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
    Robak, Tadeusz
    Jin, Jie
    Pylypenko, Halyna
    Verhoef, Gregor
    Siritanaratkul, Noppadol
    Drach, Johannes
    Raderer, Markus
    Mayer, Jiri
    Pereira, Juliana
    Tumyan, Gayane
    Okamoto, Rumiko
    Nakahara, Susumu
    Hu, Peter
    Appiani, Carlos
    Nemat, Sepideh
    Cavalli, Franco
    LANCET ONCOLOGY, 2018, 19 (11) : 1449 - 1458
  • [4] Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study
    Drach, Johannes
    Huang, Huiqiang
    Samoilova, Olga
    Belch, Andrew
    Farber, Charles
    Bosly, Andre
    Novak, Jan
    Zaucha, Jan
    Dascalescu, Angela
    Bunworasate, Udomsak
    Masliak, Zvenyslava
    Vilchevskaya, Kateryna
    Robak, Tadeusz
    Pei, Lixia
    Rooney, Brendan
    de Velde, Helgi van
    Cavalli, Franco
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 896 - 903
  • [5] Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
    Cavalli, F.
    Jin, J.
    Pylypenko, H.
    Verhoef, G.
    Siritanaratkul, N.
    Drach, J.
    Raderer, M.
    Mayer, J.
    Pereira, J.
    Tumyan, G.
    Okamoto, R.
    Nakahara, S.
    Hu, P.
    Appiani, C.
    Nemat, S.
    Robak, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 359 - 359
  • [6] Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)
    Ogura, Michinori
    Pei, Lixia
    Rooney, Brendan
    van de Velde, Helgi
    Cavalli, Franco
    BLOOD, 2014, 124 (21)
  • [7] Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)
    Drach, Johannes
    Huang, Huiqiang
    Samoilova, Olga S.
    Belch, Andrew
    Farber, Charles M.
    Bosly, Andre
    Novak, Jan
    Zaucha, Jan
    Dascalescu, Angela
    Bunworasate, Udomsak
    Masliak, Zvenyslava
    Vilchevskaya, Kateryna
    Robak, Tadeusz
    Pei, Lixia
    Rooney, Brendan
    van de Velde, Helgi
    Cavalli, Franco
    BLOOD, 2014, 124 (21)
  • [8] Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
    Offner, Fritz
    Samoilova, Olga
    Osmanov, Evgenii
    Eom, Hyeon-Seok
    Topp, Max S.
    Raposo, Joao
    Pavlov, Viacheslav
    Ricci, Deborah
    Chaturvedi, Shalini
    Zhu, Eugene
    van de Velde, Helgi
    Enny, Christopher
    Rizo, Aleksandra
    Ferhanoglu, Burhan
    BLOOD, 2015, 126 (16) : 1893 - 1901
  • [9] Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I plus BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting
    Hernandez-Rivas, Jose Angel
    Zinzani, Pier Luigi
    Jerkeman, Mats
    Harvel, Malalatiana Be
    Van Sanden, Suzy
    Diels, Joris
    Husain, Asad
    Tapprich, Christoph
    Deshpande, Sanjay
    Le Gouill, Steven
    Dreyling, Martin
    BLOOD, 2022, 140 : 3648 - 3650
  • [10] Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
    Marjolijn van Keep
    Kerry Gairy
    Divyagiri Seshagiri
    Pushpike Thilakarathne
    Dawn Lee
    BMC Cancer, 16
12345